Free Shipping | Cash on Delivery | Email : | Call : +91-888 444-5611 (9am to 7pm)



1. Craik FIM, Salthouse TA. Handbook of Aging and Cognition. Hillsdale, NJ: Erlbaum, 1992.

2. Smith GE, Petersen RC, Parisi JE, et al. Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychol Cogn 1996;3:141–7.

3. Brayne C, Gill C, Paykel ES, et al. Cognitive decline in an elderly population—a two wave study of change. Psychological Study of Medicine 1995;25:673–83.

4. Youngjohn JR, Larrabee GJ, Crook TH. Discriminating age-associated memory impairment and Alzheimer’s disease. Psychol Assess 1992;4:54–9.

5. Hänninen T. Age-associated memory impairment: A neuropsychological and epidemiological study. Neurologian klinikan julkaisusarja 1996;39 [abstract].

6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994, 684.

7. Levy R. Aging-associated cognitive decline. Int Psychogeriatr 1994;6:63–8 [review].

8. Rubin EH, Storandt M, Miller JP, et al. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol 1998;55(3):395–401.

9. Bolla KI, Lindgren KN, Bonaccorsy C, Bleecker ML. Memory complaints in older adults: Fact or fiction? Arch Neurol 1991;48:61–4.

10. Lezak M. Neuropsychological Assessment, 3rd ed. New York: Oxford, 1995.

11. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. New York: Oxford, 1991.

12. La Rue A. Aging and Neuropsychological Assessment. New York: Plenum, 1992.

13. Nussbaum, PD, ed. Handbook of Neuropsychology and Aging. New York: Plenum, 1997.

14. Ferris SH, Kluger A. Commentary on age-associated memory impairment, age-related cognitive decline and mild cognitive impairment. Aging Neuropsychol Cogn 1996;3:148–53.

15. Rediess S, Caine ED. Aging, cognition, and DSM-IV. Aging Neuropsychol Cogn 1996;3:105–17.

16. Solfrizzi V, Panza F, Torres F, et al. High monounsaturated fatty acids intake protects against age-related cognitive decline. Neurology 1999;52(8):1563–9.

17. Jarvis MJ. Does caffeine enhance absolute levels of cognitive performance? Psychopharmacology (Berl) 1993;110(1–2):45–52.

18. Joseph JA, Shukitt-Hale B, Denisova NA, et al. Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J Neurosci 1998;18(19):8047–55.

19. Perrig WJ, Perrig P, Stahelin HB. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 1997;45(6):718–24.

20. White LR, Petrovitch H, Ross GW, et al. Brain aging and midlife tofu consumption. J Am Coll Nutr 2000;19:242–55.

21. Di Carlo A, Baldereschi M, Maggi S, et al. Prevalence and risk factors of age-related cognitive decline: The Italian longitudinal study on aging (ILSA). American Academy of Neurology, 50th Annual Meeting [abstract] P04.103.

22. Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31(3):780–6.

23. Williams P, Lord SR. Effects of group exercise on cognitive functioning and mood in older women. Aust N Z J Public Health 1997;21(1):45–52.

24. Emery CF, Huppert FA, Schein RL. Relationships among age, exercise, health, and cognitive function in a British sample. Gerontologist 1995;35(3):378–85.

25. West RL, Crook TH. Video training of imagery for mature adults. Appl Cogn Psychol 1991;6: 307–20.

26. Caprio-Prevette MD, Fry PS. Memory enhancement program for community-based older adults: development and evaluation. Exp Aging Res 1996;22(3):281–303 [review].

27. Abraham IL, Neundorfer MM, Currie LJ. Effects of group interventions on cognition and depression in nursing home residents. Nurs Res 1992;41(4):196–202.

28. Cipolli C, Chiari G. [Effects of L-acetylcarnitine on mental deterioration in the aged: initial results.] Clin Ter 1990;132(6 Suppl):479–510 [in Italian].

29. Salvioli G, Neri M. L-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res 1994;20(4):169–76.

30. Genazzani E. [A controlled clinical study on the efficacy of L-acetylcarnitine in the treatment of mild to moderate mental deterioration in the aged. Conclusions.] Clin Ter 1990;132(6 Suppl):511–2.

31. Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16(2):101–6.

32. Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol 1986;24(9):511–6.

33. Passeri M, Iannuccelli M, Ciotti G, et al. Mental impairment in aging: selection of patients, methods of evaluation and therapeutic possibilities of acetyl-L-carnitine. Int J Clin Pharmacol Res 1988;8(5):367–76.

34. Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand 1990;81(3):265–70.

35. Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano) 1993;5(2):123–33.

36. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 1991;6:31–43.

37. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc 1987;35:425–30.

38. Peruzza M, DeJacobis M. A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Adv Ther 1986;3:201–9.

39. Manconi E, Binaghi F, Pitzus F. A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr Ther Res Clin Exp 1986;30:702–709.

40. Thal LJ, Salmon DP, Lasker B, et al. The safety and lack of efficacy of vinpocetine in Alzheimer~s disease. J Am Geriatr Soc 1989;37:515–20.

41. Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, et al. Therapeutic efficacy of vincamine in dementia. Neuropsychobiology 1996;34:29–35.

42. Madigan SM, Tracey F, McNulty H, et al. Riboflavin and vitamin B-6 intakes and status and biochemical response to riboflavin supplementation in free-living elderly people. Am J Clin Nutr 1998;68(2):389–95.

43. Tolonen M, Schrijver J, Westermarck T, et al. Vitamin B6 status of Finnish elderly. Comparison with Dutch younger adults and elderly. The effect of supplementation. Int J Vitam Res 1988;58(1):73–7.

44. Deijen JB, van der Beek EJ, Orlebeke JF, et al. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology (Berl) 1992;109(4):489–96.

45. Martin DC, Francis J, Protetch J, Huff FJ. Time dependency of cognitive recovery with cobalamin replacement: report of a pilot study. J Am Geriatr Soc 1992;40(2):168–72.

46. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720–8.

47. Myers BL, Badia P. Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions. Neurosci Biobehav Rev 1995;19(4):553–71. Published erratum appears in Neurosci Biobehav Rev 1996;20(2):I–IV.

48. Dollins AB, Zhdanova IV, Wurtman RJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 1994;91(5):1824–8.

49. Dori D, Casale G, Solerte SB, et al. Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia 1994;21(1–2):121–6.

50. Comperatore CA, Lieberman HR, Kirby AW, et al. Melatonin efficacy in aviation missions requiring rapid deployment and night operations. Aviat Space Environ Med 1996;67(6):520–4.

51. Jean-Louis G, von Gizycki H, Zizi F. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 1998;25(3):177–83.

52. Slotten HA, Krekling S. Does melatonin have an effect on cognitive performance? Psychoneuro-endocrinology 1996;21(8):673–80.

53. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;54:1265–72.

54. Allain H, Raoul P, Lieury A, et al. Effects of two doses of ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 1993;15(3):549–58.

55. Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo-controlled study of Ginkgo biloba extract (‘tanakan’) in elderly patients with mild to moderate memory impairment. Curr Med Res Opin 1991;12(6):350–5.

56. Brautigam MRH, Blommaert FA, Verleye G, et al. Treatment of age-related memory complaints with Ginkgo biloba extract: a randomized double-blind placebo-controlled study. Phytomedicine 1998;5:425–34.

57. Wesnes K, Simmons D, Rook M. A double-blind, placebo-controlled trial of Tanakan in the treatment of idiopathic impairment in the elderly. Human Psychopharmacol 1987;2:159–69.

58. Israel L, Dell’Accio E, Martin G, Hugonot R. Ginkgo biloba extract and memory training programs—comparative assessment on elderly outpatients. Psychologie Médicale 1987;19:1431–9.

59. Gräbel E. The influence of Ginkgo biloba extract (EGb 761) on mental performance: A double-blind study under computerized measurement conditions in patients with cerebral insufficiency. Fortschr Med 1992;110:73–6.

60. Winther K, Randlov C, Rein E, Mehlsen J. Effects of Ginkgo biloba extract on cognitive function and blood pressure in elderly subjects. Curr Ther Res 1998;59:881–8.

61. Van Dongen M, van Rossum E, Kessels AGH, et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183–94.

62. Wang Z, Ren G, Zhao Y, et al. A double-blind study of huperzine A and piracetam in patients with age-associated memory impairment and dementia. In: Kanba S, Richelson E, eds. Herbal Medicines for Nonpsychiatric Diseases. Tokyo: Seiwa Shoten Publishers, 1999, 39–50.

close window

close window